Patents by Inventor Maria G. M. Scrivens

Maria G. M. Scrivens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240093177
    Abstract: This disclosure provides compositions and methods for high throughput screening, selecting, and identifying antibodies or antibody-like molecules that bind to a target integral membrane protein.
    Type: Application
    Filed: June 12, 2023
    Publication date: March 21, 2024
    Inventors: Malgorzata Gil-Moore, Maria G.M Scrivens, Renee A. Kirk, Leslie A. Balch, Loretta L. Mueller, Ernest S. Smith
  • Patent number: 11427634
    Abstract: Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: August 30, 2022
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Angelica Cornelison, Maria G. M. Scrivens, Mark Paris, Maurice Zauderer
  • Publication number: 20210348158
    Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation on poxvirus extracellular virions and methods for screening, selecting, and identifying antibodies or antibody-like molecules that bind to a target IMP of interest.
    Type: Application
    Filed: May 5, 2021
    Publication date: November 11, 2021
    Inventors: Ernest S. Smith, Maria G.M. Scrivens, Loretta Mueller, Shuying Shi, Leslie A. Balch
  • Publication number: 20210032329
    Abstract: Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.
    Type: Application
    Filed: May 4, 2018
    Publication date: February 4, 2021
    Inventors: Ernest S. SMITH, Angelica CORNELISON, Maria G.M. SCRIVENS, Mark PARIS, Maurice ZAUDERER
  • Patent number: 10870707
    Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: December 22, 2020
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Mark Paris, Maria G. M. Scrivens, Renee A. Kirk, Angelica A. Cornelison
  • Publication number: 20200216562
    Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.
    Type: Application
    Filed: December 26, 2019
    Publication date: July 9, 2020
    Inventors: Ernest S. Smith, Mark Paris, Maria G.M. Scrivens, Renee A. Kirk, Angelica A. Cornelison
  • Patent number: 10577427
    Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: March 3, 2020
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Mark Paris, Maria G. M. Scrivens, Renee A. Kirk, Angelica A. Cornelison
  • Patent number: 10550199
    Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: February 4, 2020
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Mark Paris, Maria G. M. Scrivens, Renee A. Kirk, Angelica A. Cornelison
  • Publication number: 20190276556
    Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.
    Type: Application
    Filed: April 15, 2019
    Publication date: September 12, 2019
    Inventors: Ernest S. Smith, Mark Paris, Maria G.M. Scrivens, Renee A. Kirk, Angelica A. Cornelison
  • Publication number: 20190112388
    Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation for use in the screening, selecting, and identifying of antibodies or antibody-like molecules that bind to a target IMP of interest.
    Type: Application
    Filed: April 21, 2017
    Publication date: April 18, 2019
    Applicant: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Mark Paris, Maria G.M. Scrivens, Renee A. Kirk, Angelica A. Cornelison
  • Patent number: 7807168
    Abstract: The invention relates to antibodies which bind to tumor necrosis factor ? (TNF?) and uses thereof, in particular in the diagnosis and treatment of autoimmune diseases, e.g. rheumatoid arthritis (RA). Specific human monoclonal antibodies which inhibit TNF?-mediated signalling pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human monoclonal antibodies which block the ability of TNF? to bind to its receptor, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating autoimmune diseases, e.g. rheumatoid arthritis (RA), using antibodies of the invention.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: October 5, 2010
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Leslie A. Croy, Maria G. M. Scrivens
  • Publication number: 20080267974
    Abstract: The invention relates to antibodies which bind to tumor necrosis factor ? (TNF?) and uses thereof, in particular in the diagnosis and treatment of autoimmune diseases, e.g. rheumatoid arthritis (RA). Specific human monoclonal antibodies which inhibit TNF?-mediated signalling pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human monoclonal antibodies which block the ability of TNF? to bind to its receptor, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating autoimmune diseases, e.g. rheumatoid arthritis (RA), using antibodies of the invention.
    Type: Application
    Filed: April 9, 2008
    Publication date: October 30, 2008
    Applicant: Vaccinex, Inc.
    Inventors: Ernest S. SMITH, Leslie A. Croy, Maria G.M. Scrivens